U.S. markets open in 2 hours 51 minutes

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
165.75-3.05 (-1.81%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close168.80
Bid162.19 x 800
Ask170.63 x 800
Day's Range164.71 - 168.89
52 Week Range86.88 - 178.64
Avg. Volume730,969
Market Cap9.336B
Beta (5Y Monthly)1.08
PE Ratio (TTM)39.28
EPS (TTM)4.22
Earnings DateMay 03, 2021 - May 07, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est200.82
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
3% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Wall Street Wasn't Bothered by Jazz Pharmaceuticals' Mixed Q4 Results
    Motley Fool

    Why Wall Street Wasn't Bothered by Jazz Pharmaceuticals' Mixed Q4 Results

    The biggest news for Jazz Pharmaceuticals (NASDAQ: JAZZ) in recent months was the company's announcement earlier this month that it plans to acquire GW Pharmaceuticals in a $7.6 billion deal. Now, Jazz has more news that investors eagerly awaited. Here are the highlights from Jazz's Q4 update.

  • Jazz Pharmaceuticals PLC (JAZZ) Q4 2020 Earnings Call Transcript
    Motley Fool

    Jazz Pharmaceuticals PLC (JAZZ) Q4 2020 Earnings Call Transcript

    JAZZ earnings call for the period ending December 31, 2020.

  • Benzinga

    Recap: Jazz Pharmaceuticals Q4 Earnings

    Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 9.50% year over year to $4.00, which missed the estimate of $4.20. Revenue of $665,517,000 higher by 14.40% year over year, which beat the estimate of $639,550,000. Outlook Jazz Pharma Sees FY21 Sales $2.55B-$2.7B vs $2.56B Estimate, Adj. EPS $15.65-$16.85 vs $16.78 Estimate Conference Call Details Date: Feb 23, 2021 Time: 04:30 PM View more earnings on JAZZ ET Webcast URL: https://edge.media-server.com/mmc/p/7h5iem3y Price Action 52-week high: $172.67 Company's 52-week low was at $86.88 Price action over last quarter: Up 5.93% Company Description Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021Preview: Jazz Pharmaceuticals's Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.